CoChat
Sign Up
Cited by 179Pharmacology and Obesity TreatmentRegulation of Appetite and ObesityBariatric Surgery and Outcomes

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

Comparison of Combined Bupropion and Naltrexone Therapy for Obesity with Monotherapy and Placebo

Greenway, Frank L., Dunayevich, Eduardo, Tollefson, Gary, Erickson, Janelle, Guttadauria, Maria, Fujioka, Ken, Cowley, Michael A., for the NB-201 Study Group·2009·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2009-1350
Open this paper in CoChat — free account

Abstract

CONTEXT: The efficacy of current centrally acting obesity pharmacotherapies is limited by compensatory mechanisms that mitigate weight loss. OBJECTIVE: Our objective was to determine whether opioid receptor antagonism (naltrexone) plus pro-opiomelanocortin activation (bupropion) causes greater weight loss than placebo or monotherapy. DESIGN/SETTING: A randomized, placebo- and monotherapy-controlled, double-blind, dose-finding trial was conducted from August 2005 to December 2006 in seven U.S. outpatient clinics. PARTICIPANTS: A total of 419 patients with uncomplicated obesity participated. INTERVENTIONS: Interventions included 24 wk of sustained-release bupropion (400 mg/d), immediate-release naltrexone (48 mg/d), placebo, and three combination therapy [naltrexone/bupropion (NB)] groups consisting of immediate-release naltrexone, 16, 32, or 48 mg/d, plus sustained-release bupropion (400 mg/d) with a 24-wk extension. A minimal diet and exercise component was also included. MAIN OUTCOME MEASURES: Percent weight change from baseline at wk 24 in the intent-to-treat population for NB48 vs. placebo and monotherapy was assessed. Other measurements included body mass index, waist circumference, fasting lipids, glycemic variables, safety, and tolerability. RESULTS: At wk 24, placebo-subtracted weight loss was -4.62% [95% confidence interval (CI) -6.24 to -2.99; P < 0.001] for NB16, -4.65% (95% CI -6.20 to -3.09; P < 0.001) for NB32, and -3.53% (95% CI -5.15 to -1.90; P < 0.001) for NB48. Weight loss was statistically significant vs. monotherapy for all three NB combinations with the exception of NB48 vs. bupropion. Weight loss with NB continued after wk 24. The most common treatment-emergent adverse event was mild transient nausea. CONCLUSIONS: NB caused gradual sustained weight loss over 48 wk; NB32 and NB16 demonstrated greater weight loss in the intent-to-treat population due to lower attrition rates. Further study is needed to demonstrate long-term efficacy and safety of NB.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2009-1350

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Research works printed but not linked: 1

  1. 2001, The Surgeon General’s call to action to prevent and decrease overweight and obesity

Cited by

Sorted by citations

Items 101–178 of 178

Related

See all

Metadata

Authors
Greenway, F. L., Dunayevich, E., Tollefson, G., Erickson, J., Guttadauria, M., Fujioka, K., Cowley, M. A., & for the NB-201 Study Group
Affiliations
  • Pennington Biomedical Research Center (US)
  • Orexigen Therapeutics (United States) (US)
  • Indiana University School of Medicine (US)
  • MG Consulting, Inc. (M.G.), New York, New York 10462
  • Scripps Health (US)
Corresponding author
Greenway, Frank L.
ORCID
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2009-12-01
Volume
94
Issue
12
Pages
4898-4906
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2009-1350
OpenAlex
W2036089668
Cited by
179
References
24
Citations by year
2026: 4 · 2025: 12 · 2024: 7 · 2023: 4 · 2022: 5 · 2021: 9 · 2020: 11 · 2019: 10 · 2018: 8 · 2017: 9 · 2016: 13 · 2015: 17 · 2014: 12 · 2013: 14 · 2012: 10
FWCI
10.48
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Louisiana State University
  • Orexigen Therapeutics
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
Keywords
obesity, bupropion, naltrexone, combination pharmacotherapy, weight loss, opioid antagonism, proopiomelanocortin, sustained weight loss, dose-finding, nausea, fasting lipids, glycemic control, waist circumference, body mass index, diet and exercise, treatment discontinuation, drug safety and tolerability
MeSH terms
Adolescent, Adult, Appetite, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Naltrexone, Narcotic Antagonists, Obesity, Risk Factors, Cohort Studies, Weight Loss, Bupropion, Dopamine Uptake Inhibitors, Endpoint Determination, Positron-Emission Tomography, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review